Selank
The Anxiolytic Nootropic Peptide
Molecular Data
- Formula
- C33H57N11O9
- Molecular Weight
- 751.88 g/mol
- Sequence
- Thr-Lys-Pro-Arg-Pro-Gly-Pro
01
Overview
Selank is a synthetic heptapeptide analogue of the endogenous human peptide tuftsin, developed by the Institute of Molecular Genetics of the Russian Academy of Sciences. It is registered in Russia as an anxiolytic drug. Research highlights its ability to reduce anxiety without causing sedation or dependence, while simultaneously enhancing cognitive function.
02
Mechanism of Action
Selank stabilizes enkephalins (endogenous opioid peptides) by inhibiting their enzymatic degradation. It modulates the expression of serotonin transporter and dopamine receptor genes, and enhances the GABA-ergic system without direct receptor binding, resulting in anxiolysis without dependency.
03
Research Highlights
Registered as an anxiolytic drug in Russia under the name Selanc
Studies show significant reduction in anxiety scores comparable to fenazepam without side effects
IL-6 and interferon research shows immune-modulating activity
04
Dosage
Administration & Timing
Intranasal administration, 1–2 drops per nostril, 2–3× daily. Developed as an anxiolytic nootropic; timing independent of food.
Dosage Guidelines
Cycle Length
10–14 days; repeated cycles with 1–3 week rest periods in chronic research.
05
Reconstitution
Solvent
Sterile saline (0.9% NaCl) for intranasal formulation
Volume
Per manufacturer formulation (0.15% solution)
Concentration
0.15% aqueous solution
Storage
Refrigerate at 2–8 °C; protect from light. Discard 30 days after reconstitution.
Notes
Selank is administered intranasally. Unlike benzodiazepines, anxiolytic effects in research appear without sedation or cognitive impairment.
Research Reference Only
Dosage and reconstitution values reflect commonly cited ranges from published research literature and are presented for educational and research reference only. This is not medical advice or a dosing recommendation. HEXAGEN does not endorse human use of any compound. Always consult a qualified healthcare professional.
Research Disclaimer
Selank is for educational and research purposes only. Not intended as medical advice. Consult a qualified healthcare professional before making any health-related decisions.
Related Compounds
View All
Selank Knowledge Graph
Explore how Selank connects to mechanisms, research goals, related compounds, research stacks, and scientific references. Drag nodes, zoom, and filter by type.
No nodes match the active filters.
Selank — Common Research Questions
What is Selank?
Selank is a synthetic heptapeptide analogue of the endogenous human peptide tuftsin, developed by the Institute of Molecular Genetics of the Russian Academy of Sciences. It is registered in Russia as ... Selank belongs to the Cognitive research category and is studied for its the anxiolytic nootropic peptide.
How does Selank work?
Selank stabilizes enkephalins (endogenous opioid peptides) by inhibiting their enzymatic degradation. It modulates the expression of serotonin transporter and dopamine receptor genes, and enhances the GABA-ergic system without direct receptor binding, resulting in anxiolysis without dependency.
What are the key research benefits of Selank?
Anxiolytic effects without benzodiazepine-like sedation. Memory formation and learning enhancement. Stress resilience and mood stabilization. Immune-modulating properties through tuftsin activity. Enkephalin degradation inhibition for endogenous opioid support. Anti-depressive effects in research models.
What is the molecular structure of Selank?
Selank has the molecular formula C33H57N11O9 and a molecular weight of 751.88 g/mol. Its amino acid sequence is Thr-Lys-Pro-Arg-Pro-Gly-Pro. This structural information is important for researchers studying receptor binding and pharmacokinetics.
What does the research say about Selank?
Registered as an anxiolytic drug in Russia under the name Selanc Studies show significant reduction in anxiety scores comparable to fenazepam without side effects IL-6 and interferon research shows immune-modulating activity These findings are based on preclinical and clinical research. Selank is a research compound and these studies do not constitute medical advice.
Is Selank FDA approved?
No. Selank is not FDA-approved for any indication. It is a research chemical studied in preclinical and early clinical research. These compounds are not approved for human therapeutic use and should only be studied in appropriate research settings.
What category does Selank belong to?
Selank belongs to the Cognitive category, which focuses on peptides investigated for their nootropic and neuroprotective potential, supporting mental clarity, memory consolidation, and neurological resilience. You can explore more compounds in this category on the Cognitive pillar page.
Related Articles
Semax: BDNF Upregulation and Cognitive Enhancement
A review of Semax's mechanism — from melanocortin receptor modulation to BDNF and NGF upregulation in the hippocampus.
Dihexa: Synaptogenesis and Spatial Memory
Washington State University research on Dihexa's dramatic effects on synaptogenesis and Morris water maze performance.
Noopept: The Dipeptide Nootropic
Understanding Noopept's prodrug conversion, BDNF/NGF upregulation, and its position as a dipeptide nootropic.
Scientific References
Seregenko et al. — "Selank: anxiolytic nootropic peptide" (Acta Naturae, 2017)
Russian clinical registration as Selanc for anxiety
Registered as an anxiolytic drug in Russia under the name Selanc
Studies show significant reduction in anxiety scores comparable to fenazepam without side effects
IL-6 and interferon research shows immune-modulating activity